Objectives: To assess the cost-effectiveness of an educational intervention encouraging self-skin examinations for early detection of skin cancers among men older than 50 years. Methods: A lifetime Markov model was constructed to combine data from the Skin Awareness Trial and other published sources. The model incorporated a health system perspective and the cost and health outcomes for melanoma, squamous and basal cell carcinomas, and benign skin lesions. Key model outcomes included Australian costs (2015), quality-adjusted life-years (QALYs), life-years, and counts of skin cancers. Univariate and probabilistic sensitivity analyses were undertaken to address parameter uncertainty. Results: The mean cost of the intervention was A$5,298 compared with A$4,684 for usual care, whereas mean QALYs were 7.58 for the intervention group and 7.77 for the usual care group. The intervention was thus inferior to usual care. When only survival gain is considered, the model predicted the intervention would cost A$1,059 per life-year saved. The likelihood that the intervention was cost-effective up to A$50,000 per QALY gained was 43.9%. The model was stable to most data estimates; nevertheless, it relies on the specificity of clinical diagnosis of skin cancers and is subject to limited health utility data for people with skin lesions. Conclusions: Although the intervention improved skin checking behaviors and encouraged men to seek medical advice about suspicious lesions, the overall costs and effects from also detecting more squamous and basal cell carcinomas and benign lesions outweighed the positive health gains from detecting more thin melanomas.
Introduction
Skin cancer is a significant public health problem in many whiteskinned populations. The incidence of squamous and basal cell carcinomas (SCCs/BCCs; keratinocyte cancers) and melanoma has been increasing worldwide since the 1980s, although the incidence of melanoma may be plateauing in younger ages in the United States, Canada, and Australia [1] . Survival from melanoma is strongly negatively correlated with the extent of invasion of the tumor at diagnosis [2] . The mean 5-year survival rate after diagnosis and treatment of localized tumors is 96%, reducing to 20% for tumors that have spread to distant sites in the body [3] . Nevertheless, 2-year survival rates ($29%) have improved to 45% in some individuals with the introduction of targeted therapies (e.g., ipilimumab, dabrafenib, and pembrolizumab) for unresectable, late-stage melanomas [4] . Although it is still important to treat keratinocyte cancers, they are very common and are associated with quality-of-life impacts but do not have high mortality potential. In immunosuppressed populations such as organ transplant recipients, keratinocyte cancers are aggressive and can be fatal [5] .
Despite the poor prognosis of advanced melanoma, population-wide screening for early detection of melanoma is not endorsed by most leading health authorities [6] because of lack of evidence from randomized trials of the effectiveness of screening to reduce melanoma mortality [7] . In addition, in Germany, large-scale skin cancer screening has operated since 2008 and evaluation of this program shows that it has made no improvements to melanoma mortality [8] . The introduction of any screening program must be based on strong evidence of benefit, given that screening also causes harm to a proportion of the screened population largely because of overdiagnosis and unnecessary treatment [9] . Risk stratification to enable targeted screening of those individuals at high risk of developing melanoma is likely to improve the value of early detection initiatives [1] .
In addition to the lack of definitive evidence of benefit, there are also economic considerations. Health care expenditure for treatment of skin cancers is among the highest of all cancers in several health systems internationally [10] [11] [12] and will continue to climb with increasing skin cancer incidence and population aging. Organized melanoma screening programs are likely to incur high implementation costs on a population-wide scale, and are likely to increase the yield of (and hence cost of treating) other skin cancers and benign skin lesions that would also be detected during skin examinations. In previous skin cancer screening programs with whole-body clinical skin examination (wbCSE) [13, 14] , the number of excisions of suspicious skin lesions that were benign exceeded histopathologically confirmed skin cancers by fivefold [13] . In a German skin cancer screening study, 20 excisions were performed for every one melanoma found in men 65 years and older [13] .
Although Australia does not have a formal population-based skin cancer screening program, informal screening is frequently carried out by general practitioners (GPs) to detect keratinocyte cancer and melanoma. Relative to other segments of the population, older men are reluctant to participate in cancer screening programs or skin examinations [15] ; yet skin cancers are more common and mortality is higher in older men than in older women [15] . In response to this, the Skin Awareness Trial was undertaken to assess whether educating men older than 50 years to be skin-aware and check their own skin regularly would lead to targeted skin examinations by their GPs and subsequent earlier detection and treatment of keratinocyte cancer and melanoma [15] . As part of the overall evaluation of the intervention, a costeffectiveness analysis was also planned [15] .
Health economic studies of skin cancer prevention and early detection activities are varied and few have targeted individuals at high risk of skin cancer [16] [17] [18] [19] [20] [21] [22] . As economic analysis is relevant to any initiative proposing early detection of skin cancer, this study assessed the cost-effectiveness of the Skin Awareness Trial intervention to investigate whether the intervention would be cost-effective in the wider Australian context. A key question is whether the costs of detecting greater numbers of thin melanomas that would be expected from an early detection intervention will outweigh the inevitable costs of also finding and treating more keratinocyte cancers and benign lesions that may otherwise go undetected and, relative to melanoma, are less harmful.
Methods

Overview
A cost-effectiveness analysis was performed using data from the Skin Awareness Trial combined with data estimates from reviews of the literature. This study included both keratinocyte cancers and melanoma as the end points for screening in keeping with the intervention's goal of increasing awareness and early detection of all skin cancers and the usual clinical practice of examining skin for all types of skin cancers simultaneously. Men older than 50 years and residing in the Australian state of Queensland were selected at random from the Australian Electoral Roll (enrollment to vote is compulsory in Australia). The Skin Awareness Trial randomized 929 participants to either the intervention arm or the control arm [15] . The intervention group received an educational DVD about self-skin examination and the importance of presenting to a doctor if there were lesions of concern, postcard reminders to watch the DVD, a body chart to note down the location of skin lesions, and a colored brochure differentiating benign and malignant skin lesions. The control group received only the colored brochure. Participants completed assessments at baseline, 6 months, and 12 months. The primary outcomes were self-skin examinations, clinical skin examinations (by a GP or other doctor), self-efficacy, and perceived social support [23] . Baseline characteristics of the participants indicated that the two groups were evenly balanced with respect to demographic, socioeconomic, sun exposure, and medical history profiles with few exceptions [23] .
Markov Model
A health state transition Markov model was constructed in TreeAge Pro 2015 (TreeAge Software, Inc., Williamstown, MA). The cohort model consisted of mutually exclusive health states so that men would occupy one health state at one time. The health states included 1) melanoma (then divided into in situ or invasive melanomas, the latter branching into thicknesses of o1 mm, 1.00-1.99 mm, 2.01-4.00 mm, and 44 mm); 2) SCCs/ BCCs; 3) benign skin lesions; 4) no skin lesions/tumors; 5) five post-skin cancer states (one for each category of melanoma thickness and one for SCCs/BCCs); and 6) a "dead" state ( Fig. 1 ; see also Appendix Figure 1 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2016.12.017). The post-skin cancer states were created to allow for follow-up care, and additional skin cancers could develop. The model tracked a cohort of men with a starting age of 64 years (mean age in the Skin Awareness Trial) through yearly cycles for their remaining lifetime, up to a maximum age of 100 years. To simulate real life, the men may move between the health states when they face different probabilities of developing skin cancers or skin lesions or they can remain in the same state (e.g., staying lesion-free). They all eventually die of a melanoma, other skin cancer, or other causes. Several probabilities (e.g., risk of developing skin cancer and mortality rates) were age-dependent as the men age in the Key outcomes of the model include health care costs, qualityadjusted life-years (QALYs), life-years (survival), counts of melanomas, and counts of keratinocyte cancers. Recent guidelines for best-practice health economic modeling were adhered to during our study [24, 25] .
Model Inputs and Sources
File 1 in Supplemental Materials found at http://dx.doi.org/10. 1016/j.jval.2016.12.017 provides detailed information on the data, calculations, and tables used in the model, which are summarized here and presented in Table 1 .
Transition probabilities
In each yearly cycle, a proportion of people will either continue to live without skin cancer or develop melanoma, SCCs/BCCs, or other skin lesions. Once treated, individuals can develop subsequent skin cancers, other skin lesions, or remain lesion-free. The proportions of in situ and invasive melanomas were obtained from the Queensland Cancer Registry from 2009 to 2013 and in situ melanomas incurred the same costs and utilities as for persons with a melanoma thickness of less than 1 mm. The probabilities for developing skin cancers and lesions in the first year were taken directly from the Skin Awareness Trial data for the intervention and control groups (Table 1) . Four men were diagnosed with melanoma in this trial during the first year, and all were in the intervention group (4 of 104; 3.9%). The high volatility in this estimate was tested in sensitivity analyses using 95% confidence intervals (95% CI 0.15-7.5%). We assumed that melanoma incidence in the control group would be equal to that in the general male population depending on age group and used annual incidence rates converted to probabilities (e.g., for 60-to 64-year-old men, the probability was 0.15%). Beyond the trial period, we conservatively assumed that there would be no continuing effect of the intervention and that the proportion of men developing melanoma, SCC/BCC, or other lesions reflected age-and sex-specific national estimates of incidence [26, 27] . The occurrence of multiple skin cancers and benign lesions in an individual is common and is explicitly captured in the model. Probabilities for subsequent multiple skin lesions and tumors were based on epidemiological studies [27, 28] .
Mortality rates
Thick melanomas are associated with a higher mortality risk [29] . The model uses published evidence suggesting that wbCSE, as encouraged by the intervention, is associated with a greater proportion of thin melanoma being detected (odds ratio 1.32). Consequently, there is a reduction in mortality, relative to detection without wbCSE, which is captured in the model. Survival data were based on rates published in 2009 by Balch et al. [3] , which provided survival by tumor size (see File 1 in Supplemental Materials). In 2012, Green et al. [29] published 20-year survival data on Queensland residents with thin melanomas (o1 mm), and figures for men were used for 5-, 10-, and 20-year survival [29] . The Balch 2009 estimates for metastatic melanoma do not reflect survival gains from new therapies for metastatic melanoma that were available since 2011 in Australia. Survival rates were based from trial evidence at 1 year and 2 years for ipilimumab [30] and dabrafenib with trametinib [31] . These are now first-line treatments for 50% each of patients with advanced melanoma. A weighted average of survival was calculated. Long-term survival was assumed to be the midpoint between stage III and stage IV from Balch 2009 Kaplan-Meier curves. Probabilities were entered into the model as a time-dependent table. Annual mortality was interpolated between 2 and 5 years, 5 and 10 years, and 10 and 20 years. Mortality from SCCs/BCCs is uncommon but in 2012, 362 Australian men died from SCCs/BCCs [32] and the age-dependent mortality rate was added to the model as a table. For individuals with benign or no lesions, background mortality rates were based on Australian age-dependent mortality tables [33] for men in the general population. All mortality rates were converted to probabilities using a rate to probability formula (1 -e -rate Â time ).
Health utilities
Health utilities are similar to health-related quality-of-life scores but are developed using dedicated instruments and scoring algorithms. Utility scores are attached to particular health states for a disease and range between 0 (indicating death) and 1 (indicating best possible health). The utility score is applied to survival data to generate QALYs, the preferred outcome in economic evaluations. Utility scores for various melanoma stages were obtained from a study of 395 patients who used the EuroQol five-dimensional questionnaire (Table 1 ) [34] . Data regarding health utilities for patients with SCCs/BCCs or benign skin lesions are limited [21] . It is, however, reasonable to assume that individuals who face disfiguring, invasive, or chronic multiple skin cancers experience decrements to their quality of life, particularly for distress and depressive symptoms. Therefore, we assumed a utility score of 0.90 for patients with SCC/BCC cancers (0.85 and 0.95 in sensitivity analysis) and a disutility of À0.03 for additional SCC/BCC in subsequent years. We further assumed no disutility for benign lesions (i.e., utility of 1.0) and additional decrements of À0.03 for each year of subsequent benign lesions.
Resource use and costs
The study included resources attributed to the health system with other third-party and patient costs omitted. The Skin Awareness Trial coordinator provided costs for the resources required to implement the intervention and included staff costs for coordinating the program, consumables (e.g., postage, printing, and telecommunications), and materials (e.g., DVD production and body charts). Costs were included for resources consumed in the routine diagnosis, treatment, and follow-up of skin cancers and skin lesions in Australia (see File 1 in Supplemental Materials). Costs were included for the increased number of benign lesions treated, compared with the control group, and inherently captured "false-positive" excisions or treatments. Health care costs included GP visits for a wbCSE, pathology and excision costs for SCCs/BCCs, and various treatments (e.g., cryotherapy, excision, and topical cream [28] ) for benign lesions. The health care use for diagnosis and treatment of localized melanoma was based on a previous Australian study [35] , whereas the estimated cost of treating advanced melanoma incorporate new therapies (e.g., dabrafenib and ipilimumab) provided to eligible patients through the Pharmaceutical Benefits Scheme [4] . Resources were valued using those reported in the literature or national price schedules (e.g., Medicare Benefits Schedule and Pharmaceutical Benefits Schedule) and inflated to 2015 Australian dollars when necessary using the Cochrane CCEMG-EPPI Centre Cost Converter (http://eppi.ioe.ac.uk/costcon version/default.aspx).
Analyses
The model aggregated the probabilities and values assigned to the different health states using an expected value (mean per person) analysis, and the mean costs and QALYs for the two arms were calculated. Future costs and benefits were discounted at 5% per year to adjust to present values. A 5% discount rate was chosen in concordance with guidelines of the national health technology assessment body in Australia for pharmaceuticals [36] . The incremental cost-effectiveness ratio (ICER) was calculated as the difference in costs for the two arms divided by the difference in QALYs. Life-years, counts of all skin cancers, and counts of melanomas (all and thin melanomas [o1 mm]) were also reported as secondary outcomes.
To determine the extent of uncertainty in the modeled estimates, we undertook one-way sensitivity analyses in which each model input was varied through a range of plausible values (Table 1 ) and changes to the base results were observed. Starting age and model duration were varied and all other model parameters were tested between high and low values using the 95% CIs when available. In the absence of CIs, other values reported in the literature or Ϯ30% of the base value were applied (Table 1) . We also performed a probabilistic sensitivity analysis by resampling 5,000 times at random from assigned probability distributions for each parameter. This approach addresses the uncertainty of data estimates simultaneously using Monte-Carlo simulation. Gamma distributions were assigned for cost inputs and beta distributions to probabilities and utilities. A threshold of A$50,000 per QALY gained is often used to benchmark whether a new service is costeffective and is in line with government reimbursement decisions made in Australia [37] .
Results
For a cohort of older men over their remaining lifetime, the mean cost per person of an early detection intervention strategy for skin cancer was A$5,298 compared with A$4,684 for usual care ( Table 2 ). The corresponding mean QALYs were 7.58 for the intervention group and 7.77 for the usual care group. Therefore, because the intervention had higher mean costs and lower health gain in terms of QALYs compared with usual care, the intervention was dominated by usual care. Over a shorter 10-year duration, this situation also holds with costs for the intervention being A$2,812 compared with A$2,147 for usual care and mean QALYs of 5.19 and 5.27, respectively.
When quality-of-life effects are ignored and only survival gain is considered, the model predicted A$1,059 per life-year saved (Table 2) . Nevertheless, other secondary outcomes indicate high ICERs: A$6,089 per additional skin cancer and A$11,660 per additional melanoma detected and treated (Table 2) .
In one-way sensitivity analyses, the key drivers of the model were the proportion of men with SCCs or BCCs in the intervention and control groups (first year) and the proportion developing melanoma in the intervention group (first year) (Fig. 2) . The probability of SCCs or BCCs in the intervention group was 43.3% in the base case, and when tested between the 95% CI (33.8%-42.8%), the ICER ranged from A$1,782 per QALY to be dominated by usual care. If the probability of men in the intervention group diagnosed with SCC or BCC in the first year was less than 39.5%, or conversely the probability in the control group increased from 35.5% to 38.6%, the intervention would be considered cost-effective at these thresholds. No other variables tested over their high and low plausible values changed the ICER to being positive, indicating that the intervention remained inferior to no intervention. Figure 2 illustrates the change from the baseline ICER (dominated by usual care) for the most influential variables. No variation to cost or health utility estimates markedly changed the base findings. In probabilistic sensitivity analysis involving 5,000 simulations, the likelihood that the intervention was cost-effective up to A$50,000 per QALY gained was 43.9% (Fig. 3) . 
Discussion
The provision of a one-off video-based intervention to promote skin cancer awareness in older men may not be cost-effective in terms of QALYs. As expected, with an early detection intervention, a higher number of melanomas, SCCs, BCCs, and all other skin lesions were detected and treated than with no intervention. The model predicted more melanomas detected overall in the intervention arm and a higher proportion of thin melanomas than in the control arm-translating to slightly higher survival, quality of life, and lower costs. These lower V A L U E I N H E A L T H 2 0 ( 2 0 1 7 ) 5 9 3 -6 0 1 melanoma costs were, however, eroded by the costs for treating benign lesions, SCCs, and BCCs also found during screening and have virtually no impact on mortality but some impact on quality of life. Although the model estimated prolonged survival for the intervention group (by 0.88 years or $11 extra months over 36 years), when survival was adjusted for decrements in quality of life associated with all skin lesions, marginally fewer QALYs were found in the intervention group. An underlying driver of our findings is the accuracy of detecting keratinocyte cancers and benign lesions (and subsequently treated) in the intervention group, which in this study was based on men's self-examination followed by a skin examination by a GP. If the number of benign lesions could be reduced, the intervention would likely be costeffective. The other driver is the assumption that QALYs are lost through additional SCCs and BCCs found in the intervention group, which is based on a limited number of studies that investigated quality of life in keratinocyte cancers [38, 39] . Further research is required on health utilities of persons experiencing skin cancers and other lesions, in many cases, repeatedly over time.
In total there have been four economic modeling evaluations of melanoma screening programs: one Australian study based on a screening model [18] and three US studies [16, 20, 40] . These studies used lifetime Markov models and showed the expected downshift of melanoma cancer stage and subsequent link to improved survival [16, 20, 40] . All studies acknowledged the costs associated with increased case findings of SCC, BCC, and other skin lesions. Only one study used QALYs and it found the threshold for biennial skin checking by physicians among individuals with a family history of skin cancer to be US $80,700 per QALY gained; this rose to US $586,800 per QALY gained if screening occurred annually [20] . Collectively, despite the studies being published over 10 years ago, with less applicability to contemporary skin cancer treatments, the results indicate that screening could be cost-effective if directed only to high-risk populations such as those with a family history of melanoma [20] . This is also true of our findings if quality-of-life factors are ignored. Nevertheless, the aspects of quality of life after all skin cancers, including nonfatal, nonmetastatic skin cancers, are likely to be consequential when skin tumors can often be disfiguring, cause distress and discomfort, and many individuals experience multiple tumors of a chronic nature [41] [42] [43] . By using QALYs, which is the preferred measure in economic evaluations, our study incorporates those factors in the calculations.
Our study was based on a large randomized controlled trial in the state of Queensland that may produce reasonable estimates of the differences in wbCSE and cancers detected between study arms within this population. Evidence from a large Queensland data set was also used on the thickness of melanomas [2] . This is likely to be important because Queensland has the highest reported incidence of skin cancer. Unlike previous modeling studies, we included quality-of-life adjustments to survival and also undertook thorough sensitivity analyses to test all model parameters and assumptions on the stability of the key results. Because treatments for advanced melanoma are rapidly changing, we have also included these elements in our modeling. With these advances in melanoma treatment, there is more reason for investment in primary prevention initiatives that are highly costeffective and generally tend to be more cost-effective than early detection [44] . An advantage of the Skin Awareness Trial is that it combines elements of primary prevention (education and awareness about skin cancer) with early detection (self-skin and Fig. 3 -Results of probabilistic sensitivity analysis. Note. Each dot represents an incremental cost and incremental QALY pairing, using the assigned distributions around each model parameter, selected randomly during 5,000 iterations. Dots falling to the right of the diagonal line (the willingness-to-pay threshold of A$50,000 per QALY) are considered cost-effective. The proportion of simulations considered cost-effective is 43.9%. The oval is the 95% ellipse and represents the 95% CI. CI, confidence interval; QALY, quality-adjusted life-year.
V A L U E I N H E A L T H 2 0 ( 2 0 1 7 ) 5 9 3 -6 0 1 clinical skin examinations) in a high-risk group, albeit without risk stratification beyond age and sex. Identifying individuals at very high risk of primary malignant melanoma, on the basis of family history, number of nevi, and type I or II Fitzpatrick skin type, and offering surveillance in specialized clinics is also proposed [45, 46] as an alternative for general population screening. Targeted surveillance is already occurring in some Australian cities for organ transplant recipients.
It should be noted that the Skin Awareness Trial was originally powered to detect differences between arms in self-skin examinations rather than wbCSE or incident melanomas [15] but we have nevertheless relied on these estimates, subject to their uncertainty. Men who agreed to participate in the Skin Awareness Trial were more health conscious and concerned about skin cancer than expected in the general population, a large proportion having already had clinical skin examinations before enrollment. Also, men with low-risk factors such as dark hair and "skin that tans" were less likely to give consent for us to contact their doctor, and so we may have overestimated the number of skin cancers found [23] . The model is only as reliable as the estimates that populate it. Several assumptions were necessary and these were tested in the sensitivity analyses for their impact on the results. In particular, health utilities from most existing studies for SCCs and BCCs were considered clinically of limited value or the studies had significant limitations in quality. Therefore, health utilities were imputed on the basis of the authors' experience and knowledge of skin cancer and benchmarked against Tromme et al. [35] . In healthy individuals (those who were lesion-free), a utility of 1.0 was assumed; age-adjusted utilities for skin cancers were not available and therefore were also not used for the lesion-free population. Longer follow-up of the trial participants would have been informative to assess changes in sun protection behaviors, as well as health utilities, which might be linked to secondary prevention of skin cancers in later years. This additional data collection was, however, outside the scope of the study resources.
Early detection of cancer is intuitively appealing, especially when patients shift from advanced-to early-stage disease, and mortality and other burdens are avoided or delayed. This occurs cost-effectively with colorectal population screening programs throughout the world [47] . Skin cancer screening at a population level is altogether different because it is uncommon for persons in the general population to be diagnosed with advanced-stage melanoma. Concurrently, SCC, BCC, and early-stage melanoma are also often detected in clinical skin examinations, and although important to treat, they have little mortality potential and comparatively small effects on quality of life [43] . In the German Skin Cancer Screening program, it is not surprising that the expected mortality reductions have not materialized when high melanoma survival rates were likely from the outset. Poor adherence to screening protocols and other difficulties with screening implementation have also been raised as contributing to the lack of benefit to date in the German program [8] . Our study further supports evidence for the lack of patient benefit from screening and extends this to account for high health system burden. In terms of health policy, our study does not support the widespread implementation of early detection of skin cancer to a segment of the population known to be at high risk of melanoma mortality, because the benefits did not outweigh the costs.
Conclusions
We found that a skin awareness intervention targeting older men was unlikely to be cost-effective. Nevertheless, this outcome depends on the probability of detecting SCCs or BCCs in the intervention group, which, in this analysis, is based on the findings in the Skin Awareness Trial and diagnostic accuracy of skin lesions.
